Skip to main content

Research Repository

Advanced Search

All Outputs (58)

The Association between Circulating Branched Chain Amino Acids and the Temporal Risk of Developing Type 2 Diabetes Mellitus: A Systematic Review & Meta-Analysis (2022)
Journal Article
Ramzan, I., Ardavani, A., Vanweert, F., Mellett, A., Atherton, P. J., & Idris, I. (2022). The Association between Circulating Branched Chain Amino Acids and the Temporal Risk of Developing Type 2 Diabetes Mellitus: A Systematic Review & Meta-Analysis. Nutrients, 14(20), Article 4411. https://doi.org/10.3390/nu14204411

Introduction: Recent studies have concluded that elevated circulating branched chain amino acids (BCAA) are associated with the pathogenesis of type 2 diabetes mellitus (T2DM) and obesity. However, the development of this association over time and th... Read More about The Association between Circulating Branched Chain Amino Acids and the Temporal Risk of Developing Type 2 Diabetes Mellitus: A Systematic Review & Meta-Analysis.

Intensive glycemic control and macrovascular, microvascular, hypoglycemia complications and mortality in older (age ≥60years) or frail adults with type 2 diabetes: a systematic review and meta-analysis from randomized controlled trial and observation studies (2022)
Journal Article
Crabtree, T., Ogendo, J. J., Vinogradova, Y., Gordon, J., & Idris, I. (2022). Intensive glycemic control and macrovascular, microvascular, hypoglycemia complications and mortality in older (age ≥60years) or frail adults with type 2 diabetes: a systematic review and meta-analysis from randomized controlled trial and observation studies. Expert Review of Endocrinology and Metabolism, https://doi.org/10.1080/17446651.2022.2079495

Introduction: Guidelines for type 2 diabetes (T2D) recommend individualized HbA1c targets to take into account patient age or frailty. We synthesized evidence from randomized controlled trials and observational studies for intensive glycemic control... Read More about Intensive glycemic control and macrovascular, microvascular, hypoglycemia complications and mortality in older (age ≥60years) or frail adults with type 2 diabetes: a systematic review and meta-analysis from randomized controlled trial and observation studies.

Injectable semaglutide and reductions in HbA1c and weight in the real world in people switched from alternative glucagon-like peptide-1 receptor agonists (2022)
Journal Article
Crabtree, T. S. J., Adamson, K., Reid, H., Barnes, D., Sivappriyan, S., Bickerton, A., Gallen, I. W., Field, B. C. T., Idris, I., & Ryder, R. E. J. (2022). Injectable semaglutide and reductions in HbA1c and weight in the real world in people switched from alternative glucagon-like peptide-1 receptor agonists. Diabetes, Obesity and Metabolism, 24(7), 1398-1401. https://doi.org/10.1111/dom.14701

The ABCD semaglutide audit was designed to capture the routine clinical outcomes of people commenced on semaglutide in the UK. Previous work showed differential reductions in HbA1c and weight dependent on previous glucagon-like peptide-1 receptor ago... Read More about Injectable semaglutide and reductions in HbA1c and weight in the real world in people switched from alternative glucagon-like peptide-1 receptor agonists.

Pharmacological hypogonadism impairs molecular transducers of exercise-induced muscle growth in humans (2022)
Journal Article
Gharahdaghi, N., Rudrappa, S., Brook, M. S., Farrash, W., Idris, I., Aziz, M. H. A., Kadi, F., Papaioannou, K., Phillips, B. E., Sian, T., Herrod, P. J., Wilkinson, D. J., Szewczyk, N. J., Smith, K., & Atherton, P. J. (2022). Pharmacological hypogonadism impairs molecular transducers of exercise-induced muscle growth in humans. Journal of Cachexia, Sarcopenia and Muscle, 13(2), 1134-1150. https://doi.org/10.1002/jcsm.12843

Background: The relative role of skeletal muscle mechano-transduction in comparison with systemic hormones, such as testosterone (T), in regulating hypertrophic responses to exercise is contentious. We investigated the mechanistic effects of chemical... Read More about Pharmacological hypogonadism impairs molecular transducers of exercise-induced muscle growth in humans.

Safety and effectiveness of do-it-yourself artificial pancreas system compared with continuous subcutaneous insulin infusions in combination with free style libre in people with type 1 diabetes (2022)
Journal Article
Patel, R., Crabtree, T. S., Taylor, N., Langeland, L., Gazis, A. (., Mendis, B., Wilmot, E. G., & Idris, I. (2022). Safety and effectiveness of do-it-yourself artificial pancreas system compared with continuous subcutaneous insulin infusions in combination with free style libre in people with type 1 diabetes. Diabetic Medicine, 39(5), Article e14793. https://doi.org/10.1111/dme.14793

Aims: The use of do-it-yourself artificial pancreas systems (DIYAPS) among people with type 1 diabetes is increasing. At present, it is unclear how DIYAPS compares with other technologies such as FreeStyle Libre (FSL) and continuous subcutaneous insu... Read More about Safety and effectiveness of do-it-yourself artificial pancreas system compared with continuous subcutaneous insulin infusions in combination with free style libre in people with type 1 diabetes.

Can sodium-glucose co-transporter-2 (SGLT-2) inhibitor reduce the risk of adverse complications due to COVID-19?–Targeting hyperinflammation (2022)
Journal Article
Alshnbari, A., & Idris, I. (2022). Can sodium-glucose co-transporter-2 (SGLT-2) inhibitor reduce the risk of adverse complications due to COVID-19?–Targeting hyperinflammation. Current Medical Research and Opinion, 38(3), 357-364. https://doi.org/10.1080/03007995.2022.2027141

Sodium-glucose co-transporter-2 (SGLT-2) inhibitors are antidiabetic drugs with numerous pleiotropic and positive clinical effects, particularly regarding a reno-cardiovascular protective effect. More recent studies, including from our laboratory, ha... Read More about Can sodium-glucose co-transporter-2 (SGLT-2) inhibitor reduce the risk of adverse complications due to COVID-19?–Targeting hyperinflammation.

Cardiovascular risk profiles: A cross-sectional study evaluating the generalizability of the glucagon-like peptide-1 receptor agonist cardiovascular outcome trials REWIND, LEADER and SUSTAIN-6 to the real-world type 2 diabetes population in the United Kingdom (2021)
Journal Article
Webb, J., Mount, J., von Arx, L. B., Rachman, J., Spanopoulos, D., Wood, R., Tritton, T., Massey, O., & Idris, I. (2022). Cardiovascular risk profiles: A cross-sectional study evaluating the generalizability of the glucagon-like peptide-1 receptor agonist cardiovascular outcome trials REWIND, LEADER and SUSTAIN-6 to the real-world type 2 diabetes population in the United Kingdom. Diabetes, Obesity and Metabolism, 24(2), 289-295. https://doi.org/10.1111/dom.14580

Aims: To determine the proportion of UK patients with type 2 diabetes (T2D) who meet the cardiovascular (CV) or combined CV/core eligibility criteria used for the CV outcome trials (CVOTs) of UK-marketed glucagon-like peptide-1 receptor agonists (GLP... Read More about Cardiovascular risk profiles: A cross-sectional study evaluating the generalizability of the glucagon-like peptide-1 receptor agonist cardiovascular outcome trials REWIND, LEADER and SUSTAIN-6 to the real-world type 2 diabetes population in the United Kingdom.

Prevalence and Impact of Chronic Edema in Bariatric Patients: A LIMPRINT Study (2021)
Journal Article
Newman, A., Keeley, V., Pinnington, L., Green, C., Riches, K., Franks, P. J., Idris, I., & Moffatt, C. J. (2021). Prevalence and Impact of Chronic Edema in Bariatric Patients: A LIMPRINT Study. Lymphatic Research and Biology, 19(5), 431-441. https://doi.org/10.1089/lrb.2021.0055

Background: Chronic edema (CO) is a complex condition, arising from different factors, including immobility and obesity. Edema and obesity can have a significant impact on quality of life of patients and their families. Understanding how to manage ed... Read More about Prevalence and Impact of Chronic Edema in Bariatric Patients: A LIMPRINT Study.

Clinical cost evaluation and health benefits of post-bariatric intervention for patients with type 2 diabetes living in the UK (2021)
Journal Article
Alkharaiji, M., Anyanwagu, U., Crabtree, T., Gordon, J., & Idris, I. (2021). Clinical cost evaluation and health benefits of post-bariatric intervention for patients with type 2 diabetes living in the UK. Clinical Obesity, 11(6), Article e12486. https://doi.org/10.1111/cob.12486

To assess associated healthcare costs and risk of developing obesity-related comorbidities among patients with type 2 diabetes with severe obesity and receiving insulin treatment, following bariatric surgery (BS). A retrospective cohort study was con... Read More about Clinical cost evaluation and health benefits of post-bariatric intervention for patients with type 2 diabetes living in the UK.

Hypoglycaemia in type 2 diabetes treated with pre-mixed insulin (2021)
Journal Article
Idris, I., Annamalai, N., Aung, T., Binnian, I., Gibb, F. W., Malik, M. I. A., & Ramtoola, S. (2022). Hypoglycaemia in type 2 diabetes treated with pre-mixed insulin. Diabetic Medicine, 39(2), Article e14684. https://doi.org/10.1111/dme.14684

The burden of hypoglycaemia in type 2 diabetes is increasingly recognised, regardless of treatment regimen.1-3 However, time in hypoglycaemia for individuals with type 2 diabetes who use pre-mixed (biphasic) insulin remains unclear. The aim of our pr... Read More about Hypoglycaemia in type 2 diabetes treated with pre-mixed insulin.

Indicators of response to exercise training: A systematic review and meta-analysis (2021)
Journal Article
Ardavani, A., Aziz, H., Phillips, B. E., Doleman, B., Ramzan, I., Mozaffar, B., Atherton, P. J., & Idris, I. (2021). Indicators of response to exercise training: A systematic review and meta-analysis. BMJ Open, 11(7), Article e044676. https://doi.org/10.1136/bmjopen-2020-044676

Background Means-based analysis of maximal rate of oxygen consumption (VO 2max) has traditionally been used as the exercise response indicator to assess the efficacy of endurance (END), high intensity interval (HIIT) and resistance exercise training... Read More about Indicators of response to exercise training: A systematic review and meta-analysis.

Lower risk of hospitalization for heart failure, kidney disease and death with sodium-glucose co-transporter-2 inhibitors compared with dipeptidyl peptidase-4 inhibitors in type 2 diabetes regardless of prior cardiovascular or kidney disease: A retrospective cohort study in UK primary care (2021)
Journal Article
Idris, I., Zhang, R., Mamza, J. B., Ford, M., Morris, T., Banerjee, A., Khunti, K., Tulip, J., & Greener, M. (2021). Lower risk of hospitalization for heart failure, kidney disease and death with sodium-glucose co-transporter-2 inhibitors compared with dipeptidyl peptidase-4 inhibitors in type 2 diabetes regardless of prior cardiovascular or kidney disease: A retrospective cohort study in UK primary care. Diabetes, Obesity and Metabolism, 23(10), 2207-2214. https://doi.org/10.1111/dom.14437

Aim: To assess if sodium-glucose co-transporter-2 inhibitors (SGLT2is) reduce the risk of all-cause mortality, cardiovascular death and hospitalization for heart failure (HF) or chronic kidney disease (CKD) to a greater extent than dipeptidyl peptida... Read More about Lower risk of hospitalization for heart failure, kidney disease and death with sodium-glucose co-transporter-2 inhibitors compared with dipeptidyl peptidase-4 inhibitors in type 2 diabetes regardless of prior cardiovascular or kidney disease: A retrospective cohort study in UK primary care.

A novel dietary intervention reduces circulatory branched-chain amino acids by 50%: A pilot study of relevance for obesity and diabetes (2020)
Journal Article
Ramzan, I., Taylor, M., Phillips, B., Wilkinson, D., Smith, K., Hession, K., Idris, I., & Atherton, P. (2021). A novel dietary intervention reduces circulatory branched-chain amino acids by 50%: A pilot study of relevance for obesity and diabetes. Nutrients, 13(1), Article 95. https://doi.org/10.3390/nu13010095

© 2020 by the authors. Licensee MDPI, Basel, Switzerland. Elevated circulating branched-chain amino acids (BCAAs; isoleucine, leucine, and valine) are associated with obesity and type 2 diabetes (T2D). Reducing circulatory BCAAs by dietary restrictio... Read More about A novel dietary intervention reduces circulatory branched-chain amino acids by 50%: A pilot study of relevance for obesity and diabetes.

Phenylbutyrate, a branched-chain amino acid keto dehydrogenase activator, promotes branched-chain amino acid metabolism and induces muscle catabolism in C2C12 cells (2020)
Journal Article
Crossland, H., Smith, K., Idris, I., Phillips, B. E., Atherton, P. J., & Wilkinson, D. J. (2021). Phenylbutyrate, a branched-chain amino acid keto dehydrogenase activator, promotes branched-chain amino acid metabolism and induces muscle catabolism in C2C12 cells. Experimental Physiology, 106(3), 585-592. https://doi.org/10.1113/EP089223

New Findings: What is the central question of this study? The compound sodium phenylbutyrate (PB) has been shown to promote branched-chain amino acid (BCAA) catabolism, and as such has been proposed as a treatment for disorders with enhanced BCAA lev... Read More about Phenylbutyrate, a branched-chain amino acid keto dehydrogenase activator, promotes branched-chain amino acid metabolism and induces muscle catabolism in C2C12 cells.

Diuretics and risk of lower extremity amputation amongst patients with insulin-treated type 2 diabetes – exploring the mechanism of possible sodium glucose co-transporter 2 inhibitor induced risk of lower extremity amputations (2020)
Journal Article
Alshnbari, A., Alkharaiji, M., Anyanwagu, U., & Idris, I. (2020). Diuretics and risk of lower extremity amputation amongst patients with insulin-treated type 2 diabetes – exploring the mechanism of possible sodium glucose co-transporter 2 inhibitor induced risk of lower extremity amputations. Current Medical Research and Opinion, 36(12), 1985-1989. https://doi.org/10.1080/03007995.2020.1840340

Aims and background: Sodium-glucose cotransporter-2 (SGLT2) inhibitor has been linked to an increased risk of lower extremity amputation (LEA) in patients with Type 2 Diabetes (T2D) and is known to induce volume depletion through osmotic diuresis. We... Read More about Diuretics and risk of lower extremity amputation amongst patients with insulin-treated type 2 diabetes – exploring the mechanism of possible sodium glucose co-transporter 2 inhibitor induced risk of lower extremity amputations.

Glucagon-like peptide 1 infusions overcome anabolic resistance to feeding in older human muscle (2020)
Journal Article
Abdulla, H., Phillips, B. E., Wilkinson, D. J., Limb, M., Jandova, T., Bass, J. J., Rankin, D., Cegielski, J., Sayda, M., Crossland, H., Williams, J. P., Smith, K., Idris, I., & Atherton, P. J. (2020). Glucagon-like peptide 1 infusions overcome anabolic resistance to feeding in older human muscle. Aging Cell, 19(9), Article e13202. https://doi.org/10.1111/acel.13202

© 2020 The Authors. Aging Cell published by Anatomical Society and John Wiley & Sons Ltd Background: Despite its known insulin-independent effects, glucagon-like peptide-1 (GLP-1) role in muscle protein turnover has not been explored under fed-stat... Read More about Glucagon-like peptide 1 infusions overcome anabolic resistance to feeding in older human muscle.

Effect of Sodium-Glucose Cotransporter-2 Inhibitors on Endothelial Function: A Systematic Review of Preclinical Studies (2020)
Journal Article
Alshnbari, A. S., Millar, S. A., O’Sullivan, S. E., & Idris, I. (2020). Effect of Sodium-Glucose Cotransporter-2 Inhibitors on Endothelial Function: A Systematic Review of Preclinical Studies. Diabetes Therapy, 11, 1947–1963. https://doi.org/10.1007/s13300-020-00885-z

Introduction

While the beneficial effects of sodium-glucose cotransporter-2 (SGLT-2) inhibitors on cardiovascular and renal outcomes are recognized, their direct effects on endothelial function remain unclear. We, therefore, undertook a systematic... Read More about Effect of Sodium-Glucose Cotransporter-2 Inhibitors on Endothelial Function: A Systematic Review of Preclinical Studies.

Effect of Bariatric Surgery on Diagnosed Chronic Kidney Disease and Cardiovascular Events in Patients with Insulin-treated Type 2 Diabetes: a Retrospective Cohort Study from a Large UK Primary Care Database (2020)
Journal Article
Alkharaiji, M., Anyanwagu, U., Donnelly, R., & Idris, I. (2020). Effect of Bariatric Surgery on Diagnosed Chronic Kidney Disease and Cardiovascular Events in Patients with Insulin-treated Type 2 Diabetes: a Retrospective Cohort Study from a Large UK Primary Care Database. Obesity Surgery, 30(5), 1685–1695. https://doi.org/10.1007/s11695-019-04201-y

Aims: To compare the effect of bariatric surgery on renal, chronic kidney disease (CKD), and cardiovascular (CV) outcomes among obese patients with insulin-treated type 2 diabetes (T2D) with and without microalbuminuria (i.e. uACR > 3.0 mg/mmol).... Read More about Effect of Bariatric Surgery on Diagnosed Chronic Kidney Disease and Cardiovascular Events in Patients with Insulin-treated Type 2 Diabetes: a Retrospective Cohort Study from a Large UK Primary Care Database.

Evaluation of liver function tests and risk score assessment to screen patients for significant liver disease prior to bariatric and metabolic surgery (2020)
Journal Article
Antipass, A., Austin, A., Awad, S., Hughes, D., & Idris, I. (2020). Evaluation of liver function tests and risk score assessment to screen patients for significant liver disease prior to bariatric and metabolic surgery. Obesity Surgery, 30, 2840–2843. https://doi.org/10.1007/s11695-020-04486-4

Bariatric and metabolic surgery is associated with significant improvement in obesity-related comorbidities, but for patients with non-alcoholic fatty liver disease (NAFLD), clinical outcomes are dependent on the severity of liver disease, i.e. impro... Read More about Evaluation of liver function tests and risk score assessment to screen patients for significant liver disease prior to bariatric and metabolic surgery.